期刊
EXPERT OPINION ON EMERGING DRUGS
卷 26, 期 3, 页码 231-243出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728214.2021.1947240
关键词
GLP-1; semaglutide; tirzepatide; obesity; glutazumab; cagrilintide
Obesity is a serious public health threat, with over 1.1 billion individuals projected to have obesity in 2030 if current trends continue. There is a strong interest in developing obesity treatments based on GLP-1 agonism, with many novel compounds in clinical development aiming to target the GLP-1 receptor or other hormonal systems involved in energy balance and metabolism. Semaglutide is the most advanced compound in clinical development and may become a benchmark for novel anti-obesity compounds utilizing GLP-1 receptor agonism.
Introduction: Obesity is a growing threat to public health, increasing risks of numerous diseases and mortality, and impairing quality of life. If current trends continue, more than 1.1 billion individuals will have obesity in 2030, corresponding to almost 2.5 times the number of adults currently living with diabetes. There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonism, which have proved to limit morbidity and mortality in type 2 diabetes. Areas covered: This review provides an overview of current compounds containing GLP-1 receptor agonism in clinical development for obesity, with mono-activity at the GLP-1 receptor (PF-0688296, glutazumab, semaglutide) or engaging one or more other endogenous hormonal systems involved in energy balance and metabolism, including glucagon, oxyntomodulin, glucose-dependent inhibitory peptide and amylin (CT-868, CT-388, AMG 133, tirzepatide, NNC9204-1177, JNJ-54,728,518, SAR425899, pegapamodutide, MK8521, cotadutide, efinopegdutide, BI-456,906, cagrilintide + semaglutide 2,4 mg, HM15211, NNC9204-1706). Expert opinion: Many novel compounds employing GLP-1 receptor agonism are in clinical development. Semaglutide is farthest in clinical development and will presumably become a benchmark for this class of novel anti-obesity compounds.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据